Conservative Management of Endometrial Cancer

Recommendations for extracellular vesicle miRNA biomarker research in the endometrial cancer context

“…Current gold-standard treatment for EC, including early stage cancers, involves a total hysterectomy and bilateral salpingo-oophorectomy, resulting in fertility loss and early entry into menopause [6] . While unsuitable for more aggressive histological (serous) and molecular (p53 abnormal) subtypes, progestin-based treatment is gaining traction as alternative treatment for early stage, low grade ECs, however pipelle biopsies are required every three to six months during progestin therapy to monitor treatment response [7] . Biomarkers present in bodily fluids provide an opportunity to reduce the need for these invasive biopsies, lessening the burden on both patients and clinicians.…”